Focusing on Antimicrobial Resistance (AMR): Germany & Switzerland
Explore and exploit the collaboration, growth and innovation opportunities that exist in a specific business market
Delivered by Innovate UK EDGE, the programme consists of a preparation phase, a five-day innovation visit focussed on Antimicrobial Resistance (AMR), a post-visit exploitation workshop and support for approximately 12 months from an Innovate UK EDGE Innovation and Growth Specialist.
The programme is designed to help your business maximise the opportunities identified, including developing innovation projects with partners in the territory.
Innovate UK is committed to improving the diversity of who we support. As such, we welcome applications from under-represented groups.
Why Germany & Switzerland?
Germany is a key player in AMR; its Federal Ministry of Health invested more than EUR 56 million to fund the German Antibiotic Resistance Strategy to develop new treatments for bacterial infections and currently hosts the secretariat for the Global AMR Research and Development Collaboration Hub.
The 7th AMR Conference will be held in Basel, Switzerland focusing on Novel Antimicrobials & AMR Diagnostics. The innovation visit will include access to both days of the conference providing opportunities to hear from world-leading AMR experts, as well as 1-to-1 matchmaking meetings to find new collaborators and partners and to grow your business.
Focus Areas
This initiative is particularly relevant for businesses with a focus of Antimicrobials, Microbial Diagnostics or Prevention & Vaccination at the core of their value proposition.
Benefits
- Explore opportunities for AMR collaboration in Germany and Switzerland
- Visit major tech clusters and international AMR Conference to gain a better understanding of the challenges and opportunities of doing business in these markets
- Meet key AMR players
- Find potential innovation collaborators and partners, and develop your network in the UK and globally
- Improve your company value proposition to international partners and investors
Apply by 5th December.